Skip to main content
. Author manuscript; available in PMC: 2016 Sep 1.
Published in final edited form as: Virology. 2015 May 15;483:126–140. doi: 10.1016/j.virol.2015.04.017

Figure 4. Suit2 cell viability following infection with VSV recombinants.

Figure 4

Suit2 cells were mock treated or infected with VSV, VSV-p53wt, VSV-p53-CC, or VSV-p53-CC/fs viruses at MOI 0.002 or 0.00002. Cell viability was analyzed 1, 24, 48, and 96 h p.i. by MTT cell viability assay and is expressed as a percentage of mock-treated cells. All MTT assays were done in triplicate, and the data represent the means ±SEM.